However, the prognosis of patients with wt-EGFR has not improved significantly, and platinum-based chemotherapy remains the backbone therapy for wt-EGFR NSCLC patients who cannot receive the corresponding targeted drugs. Here, EGFR is linked to non-small cell lung carcinoma.